EICHORCondition: Refractory Immune-mediated Necrotizing Myopathy · Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| China-Japan Friendship Hospital | Beijing, Beijing Municipality, China | — |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | — |
| Huashan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | — |
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07752264